MX2020013953A - Composiciones de virus adenoasociado (aav). - Google Patents
Composiciones de virus adenoasociado (aav).Info
- Publication number
- MX2020013953A MX2020013953A MX2020013953A MX2020013953A MX2020013953A MX 2020013953 A MX2020013953 A MX 2020013953A MX 2020013953 A MX2020013953 A MX 2020013953A MX 2020013953 A MX2020013953 A MX 2020013953A MX 2020013953 A MX2020013953 A MX 2020013953A
- Authority
- MX
- Mexico
- Prior art keywords
- aav
- aav compositions
- compositions
- administration
- intraparenchymal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862696792P | 2018-07-11 | 2018-07-11 | |
| PCT/US2019/041398 WO2020014479A1 (en) | 2018-07-11 | 2019-07-11 | Aav compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013953A true MX2020013953A (es) | 2021-03-09 |
Family
ID=69142590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013953A MX2020013953A (es) | 2018-07-11 | 2019-07-11 | Composiciones de virus adenoasociado (aav). |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12553062B2 (https=) |
| EP (1) | EP3820490A4 (https=) |
| JP (1) | JP2021532071A (https=) |
| KR (1) | KR20210032984A (https=) |
| CN (1) | CN112469427A (https=) |
| AU (1) | AU2019299964A1 (https=) |
| BR (1) | BR112021000327A2 (https=) |
| CA (1) | CA3104196A1 (https=) |
| CO (1) | CO2020016147A2 (https=) |
| IL (1) | IL279537A (https=) |
| MX (1) | MX2020013953A (https=) |
| SG (1) | SG11202012946RA (https=) |
| WO (1) | WO2020014479A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012018628A1 (en) | 2010-07-26 | 2012-02-09 | Board Of Regents, The University Of Texas System | Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine |
| US9974850B2 (en) | 2013-01-25 | 2018-05-22 | Board Of Regents, The University Of Texas System | Immunogenic compositions and uses thereof |
| EP3510161A4 (en) | 2016-08-23 | 2020-04-22 | Akouos, Inc. | COMPOSITIONS AND METHODS FOR TREATING PERSONAL HEARING LOSS IN A PERSON |
| KR20220157944A (ko) | 2020-02-21 | 2022-11-29 | 아카우오스, 인크. | 인간 대상체에서 비-연령-연관 청각 장애를 치료하기 위한 조성물 및 방법 |
| AU2021265768B2 (en) * | 2020-04-27 | 2023-03-30 | 4D Molecular Therapeutics Inc. | Adeno-associated variants, formulations and methods for pulmonary delivery |
| WO2022236008A1 (en) * | 2021-05-07 | 2022-11-10 | Board Of Regents, The University Of Texas System | Methods and compositions for transport, storage, and delivery of adeno-associated viral vector and other molecules |
| CN117980471A (zh) | 2021-08-04 | 2024-05-03 | 武田药品工业株式会社 | 阳离子交换剂上的腺相关病毒分离 |
| US20230090654A1 (en) * | 2021-08-24 | 2023-03-23 | Homology Medicines, Inc. | Adeno-associated virus formulations |
| CN116350801A (zh) * | 2022-11-22 | 2023-06-30 | 四川至善唯新生物科技有限公司 | 一种重组腺相关病毒载体的药物组合物及其用途 |
| WO2025076729A1 (zh) * | 2023-10-11 | 2025-04-17 | 朗信启昇(苏州)生物制药有限公司 | 包含aav的药物组合物及其制备方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8801338D0 (en) | 1988-01-21 | 1988-02-17 | Quadrant Bioresources Ltd | Preservation of viruses |
| EP0728195A1 (en) | 1993-10-12 | 1996-08-28 | Chiron Corporation | Methods for preserving recombinant viruses |
| PT1061955E (pt) | 1998-03-13 | 2005-08-31 | Wyeth Corp | Composicao de polinucleotido, metodo de preparacao e sua utilizacao |
| US6759050B1 (en) | 1998-12-03 | 2004-07-06 | Avigen, Inc. | Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith |
| JP5118798B2 (ja) | 2000-03-07 | 2013-01-16 | メルク・シャープ・エンド・ドーム・コーポレイション | アデノウイルス製剤 |
| US20030153065A1 (en) | 2002-01-14 | 2003-08-14 | Genvec, Inc. | Composition and method for maintaining non-enveloped viral vectors |
| BRPI0511764B8 (pt) | 2004-06-01 | 2021-05-25 | Avigen Inc | método de prevenção de agregação de vírions de vírus adeno-associado recombinante (raav) em uma preparação purificada de virions raav |
| CA2722238C (en) | 2008-04-22 | 2017-11-28 | Life Sciences Research Partners Vzw | Liver-specific nucleic acid regulatory elements and methods and use thereof |
| PL4218797T3 (pl) * | 2009-09-21 | 2025-02-10 | Takeda Pharmaceutical Company Limited | Stabilizowane płynne i liofilizowane preparaty adamts13 |
| IT1405793B1 (it) | 2010-10-15 | 2014-01-24 | Univ Ferrara | Molecola di u1snrna umano modificato, gene codificante per la molecola di u1snrna umano modificato, vettore di espressione includente il gene, e loro uso in terapia genica |
| EP2646051A4 (en) * | 2010-12-02 | 2014-05-28 | Oncolytics Biotech Inc | FORMULATIONS OF LIQUID VIRUSES |
| MX349294B (es) | 2010-12-02 | 2017-07-21 | Oncolytics Biotech Inc | Formulaciones virales liofilizadas. |
| WO2013036961A1 (en) | 2011-09-09 | 2013-03-14 | Api Genesis Llc | A pain relief composition, comprising a trpv1 selective agonist, and manufacture and uses thereof |
| US10093947B2 (en) | 2012-02-28 | 2018-10-09 | Cornell University | AAV-directed persistent expression of an anti-nicotine antibody gene for smoking cessation |
| US9254332B2 (en) | 2013-03-15 | 2016-02-09 | Arecor Limited | Stable aqueous formulations of adenovirus vectors |
| WO2015040234A1 (en) * | 2013-09-23 | 2015-03-26 | Crucell Holland B.V. | Adenovirus formulations |
| GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| WO2016004319A1 (en) | 2014-07-02 | 2016-01-07 | University Of Florida Research Foundation, Inc. | Compositions and methods for purifying recombinant adeno-associated virus |
| WO2016154055A1 (en) | 2015-03-20 | 2016-09-29 | Bluebird Bio, Inc. | Vector formulations |
| EP3384015A4 (en) * | 2015-12-01 | 2019-05-29 | Spark Therapeutics, Inc. | SCALABLE PROCESS FOR THE PREPARATION OF A RECOMBINANT ADENO ASSOCIATED VIRAL VECTOR IN A SERUM-FREE SUSPENSION CELL CULTURE SYSTEM SUITABLE FOR THE CLINICAL APPLICATION |
| BR112019009113A2 (pt) * | 2016-11-04 | 2019-07-16 | Baxalta Incorporated | formulações de vírus adenoassociado |
| CA3040288A1 (en) * | 2016-11-04 | 2018-07-12 | Baxalta Incorporated | Adeno-associated virus purification methods |
| JP2021505610A (ja) * | 2017-12-05 | 2021-02-18 | アプライド ジェネティック テクノロジーズ コーポレイション | ウイルス粒子のための製剤最適化 |
| EP3731863A4 (en) * | 2017-12-29 | 2021-10-27 | Baxalta Incorporated | ADENO-ASSOCIATED VIRUS CLEANSING PROCEDURES |
-
2019
- 2019-07-11 KR KR1020217003809A patent/KR20210032984A/ko active Pending
- 2019-07-11 US US17/258,516 patent/US12553062B2/en active Active
- 2019-07-11 JP JP2020572381A patent/JP2021532071A/ja active Pending
- 2019-07-11 CN CN201980046282.XA patent/CN112469427A/zh active Pending
- 2019-07-11 CA CA3104196A patent/CA3104196A1/en active Pending
- 2019-07-11 AU AU2019299964A patent/AU2019299964A1/en not_active Abandoned
- 2019-07-11 MX MX2020013953A patent/MX2020013953A/es unknown
- 2019-07-11 EP EP19833959.0A patent/EP3820490A4/en active Pending
- 2019-07-11 WO PCT/US2019/041398 patent/WO2020014479A1/en not_active Ceased
- 2019-07-11 BR BR112021000327-4A patent/BR112021000327A2/pt unknown
- 2019-07-11 SG SG11202012946RA patent/SG11202012946RA/en unknown
-
2020
- 2020-12-17 IL IL279537A patent/IL279537A/en unknown
- 2020-12-23 CO CONC2020/0016147A patent/CO2020016147A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3104196A1 (en) | 2020-01-16 |
| WO2020014479A1 (en) | 2020-01-16 |
| US20210163990A1 (en) | 2021-06-03 |
| CO2020016147A2 (es) | 2021-01-29 |
| EP3820490A4 (en) | 2022-06-08 |
| US12553062B2 (en) | 2026-02-17 |
| BR112021000327A2 (pt) | 2021-04-06 |
| SG11202012946RA (en) | 2021-02-25 |
| EP3820490A1 (en) | 2021-05-19 |
| JP2021532071A (ja) | 2021-11-25 |
| AU2019299964A1 (en) | 2021-01-21 |
| IL279537A (en) | 2021-01-31 |
| KR20210032984A (ko) | 2021-03-25 |
| CN112469427A (zh) | 2021-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020013953A (es) | Composiciones de virus adenoasociado (aav). | |
| CO2017013287A2 (es) | Composiciones que comprenden una cepa bacteriana del género roseburia | |
| AR122050A2 (es) | Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes | |
| MX2018015184A (es) | Métodos para el diagnóstico de infecciones bacterianas y virales. | |
| AR105470A1 (es) | Métodos para inducir una respuesta inmune | |
| CL2020001262A1 (es) | Plataforma de presentación en endosporas basadas en paenibacillus, productos y métodos relacionados. | |
| CL2017002454A1 (es) | Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina | |
| CO2017013231A2 (es) | Composiciones que comprenden una cepa bacteriana del género parabacteroides | |
| AR130990A2 (es) | Vectores aav recombinantes que expresan genes osteoprotectores, que incluyen has2 y lubricina, de utilidad en el tratamiento de la osteoartritis y afecciones articulares relacionadas en mamíferos | |
| MX2022001776A (es) | Terapias de combinacion de inmuno oncologia con conjugados de il-2. | |
| MX360728B (es) | Metodos y composiciones para virus vivos atenuados. | |
| AR118734A1 (es) | Formulaciones y métodos de vectores de virus adenoasociados | |
| DOP2018000290A (es) | Formulación farmacéutica líquida estable | |
| CO2018011733A2 (es) | Composición farmacéutica | |
| MX2017010872A (es) | Composiciones que comprenden combinaciones de cannabinoides purificados, con al menos uno de flavonoides, terpenos o minerales. | |
| BRPI1013780A2 (pt) | composições para imunização contra staphylococcus aureus. | |
| CL2017003152A1 (es) | Composiciones de hidroxipropil beta-ciclodextrina y métodos | |
| AR093578A1 (es) | Metodos para la elaboracion de polipeptidos procesados proteoliticamente | |
| AR111373A1 (es) | Enzimas de lactasa con propiedades mejoradas | |
| MX2018014916A (es) | Formulaciones de oxido de polialquileno-asparaginasa y metodos de preparacion y uso del mismo. | |
| ES2682981T3 (es) | Proteínas de hemaglutinina del virus de la gripe y método de uso de las mismas | |
| AR099838A1 (es) | Formulación de factor ix liofilizada, vial, kit y método para producir un polvo liofilizado | |
| PE20161406A1 (es) | Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas | |
| CL2021003295A1 (es) | Composiciones de virus adenoasociados para la transferencia del gen de arsa y métodos de uso de las mismas. | |
| CL2018002548A1 (es) | Regulación del metabolismo de ornitina para aumentar el contenido de glicoformas ricas en manosa de proteínas recombinantes.(divisional solicitud 201601786) |